



HUMAN GROWTH HORMONE SUPPLY AGREEMENT

Singapore and Australia. Friday 3 February, 2006. SciGen announces that it has received a letter from Ferring AG, which acquired SciGen supplier Biotechnology General last year, terminating its Supply Agreement of Human Growth Hormone for Singapore and S. Korea. Currently, SciGen and Ferring are in negotiations to explore continued collaboration in marketing the product in these two markets. Such termination will not have material effect in SciGen's revenues. SciGen has taken measures to ensure an uninterrupted supply to its customers and in so doing, protect its franchise throughout the Asia-Pacific Region.

About SciGen

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Fay Weston Buchan Consulting +61 2 9237 2800 +61 422 206 036 (mobile) fweston@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)